Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy.However,to date,there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patients with high- Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy. Now, to date, there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patients with high-